ArticleBiometals : an international journal on the role of metal ions in biology, biochemistry, and medicine2026
Dioxazolium desferrioxamine as a cell permeant chelator of intracellular labile iron.
Article in Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Conjugates of desferrioxamine with 5-aminolevulinic or γ-aminobutyric acid: synthesis, theoretical studies, iron-chelating ability, and penetration in human Caco-2 cells.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Desferrioxamine (DFO), a clinically used chelator for iron overload, has poor cell permeability, leading to its limited ability to chelate intracellular labile iron pool (LIP). Herein, a dioxazole masking group has been introduced for one of the hydroxamate groups of DFO in an endeavor to decrease its hydrophilicity. The masking group got deprotected selectively in presence of labile iron, thereby regenerating the hexadentate complex DFO-Fe, eliminating the chances of forming toxic partially chelated complexes. The iron binding abilities and the antioxidant properties of the DFO-derivative were found to be similar to DFO. The ability to chelate intracellular LIP in iron-overloaded cells was found to be higher in the Dioxazolium-DFO compared to DFO. This opens up a new avenue in using dioxazolium masking group for hydrophilic cell-impermeable drugs belonging to hydroxamate group.
Indexed as
Identifiers
41845006What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.